Cassava Sciences | PTIE - Cash And Equivalent


Cassava Sciences reported $106.08M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
Cara Therapeutics USD 21.42M 770K Sep/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Geron USD 79.44M 553K Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 240.63M 27.39M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025